Biocon Ltd has launched BASALOG, a long acting (24 hours) peak less human insulin analogue, Glargine. The product is available in India in 10 ml and 3 ml vials.
Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon stated, "Diabetes is a debilitating disease that is pervading global populations like a pandemic with India at its epicenter. Biocon is a committed to developing affordable Insulin based therapies to manage this disease burden."
|
